nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—CYP1A2—type 2 diabetes mellitus	0.271	1	CbGaD
Leflunomide—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.0373	0.0898	CbGbCtD
Leflunomide—ABCG2—Glyburide—type 2 diabetes mellitus	0.0372	0.0894	CbGbCtD
Leflunomide—CYP2C9—Glipizide—type 2 diabetes mellitus	0.0341	0.0821	CbGbCtD
Leflunomide—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.0317	0.0763	CbGbCtD
Leflunomide—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.0276	0.0665	CbGbCtD
Leflunomide—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.027	0.0649	CbGbCtD
Leflunomide—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.027	0.0649	CbGbCtD
Leflunomide—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.0249	0.0599	CbGbCtD
Leflunomide—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.024	0.0578	CbGbCtD
Leflunomide—CYP2C9—Valsartan—type 2 diabetes mellitus	0.022	0.0529	CbGbCtD
Leflunomide—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.0218	0.0523	CbGbCtD
Leflunomide—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.0206	0.0495	CbGbCtD
Leflunomide—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.0204	0.0492	CbGbCtD
Leflunomide—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.0196	0.0471	CbGbCtD
Leflunomide—CYP1A2—Losartan—type 2 diabetes mellitus	0.014	0.0337	CbGbCtD
Leflunomide—CYP2C9—Glyburide—type 2 diabetes mellitus	0.0138	0.0332	CbGbCtD
Leflunomide—CYP2C9—Losartan—type 2 diabetes mellitus	0.0126	0.0304	CbGbCtD
Leflunomide—DHODH—adipose tissue—type 2 diabetes mellitus	0.00146	0.114	CbGeAlD
Leflunomide—AHR—islet of Langerhans—type 2 diabetes mellitus	0.00119	0.0931	CbGeAlD
Leflunomide—PTK2B—cardiovascular system—type 2 diabetes mellitus	0.00105	0.0819	CbGeAlD
Leflunomide—PTK2B—kidney—type 2 diabetes mellitus	0.00103	0.0801	CbGeAlD
Leflunomide—DHODH—liver—type 2 diabetes mellitus	0.00102	0.0799	CbGeAlD
Leflunomide—AHR—nephron tubule—type 2 diabetes mellitus	0.00096	0.075	CbGeAlD
Leflunomide—PTK2B—adipose tissue—type 2 diabetes mellitus	0.000925	0.0722	CbGeAlD
Leflunomide—AHR—pancreas—type 2 diabetes mellitus	0.000838	0.0654	CbGeAlD
Leflunomide—AHR—cortex of kidney—type 2 diabetes mellitus	0.000822	0.0642	CbGeAlD
Leflunomide—AHR—adipose tissue—type 2 diabetes mellitus	0.000761	0.0594	CbGeAlD
Leflunomide—PTK2B—liver—type 2 diabetes mellitus	0.000649	0.0506	CbGeAlD
Leflunomide—AHR—liver—type 2 diabetes mellitus	0.000533	0.0416	CbGeAlD
Leflunomide—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000372	0.0291	CbGeAlD
Leflunomide—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.000306	0.0239	CbGeAlD
Leflunomide—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000295	0.023	CbGeAlD
Leflunomide—Niflumic Acid—PTGS2—type 2 diabetes mellitus	0.00027	1	CrCbGaD
Leflunomide—ABCG2—liver—type 2 diabetes mellitus	0.000207	0.0162	CbGeAlD
Leflunomide—CYP1A2—liver—type 2 diabetes mellitus	0.000199	0.0155	CbGeAlD
Leflunomide—CYP2C9—liver—type 2 diabetes mellitus	0.000189	0.0148	CbGeAlD
Leflunomide—Headache—Glimepiride—type 2 diabetes mellitus	8.44e-05	0.000408	CcSEcCtD
Leflunomide—Ill-defined disorder—Losartan—type 2 diabetes mellitus	8.42e-05	0.000408	CcSEcCtD
Leflunomide—Cough—Irbesartan—type 2 diabetes mellitus	8.42e-05	0.000407	CcSEcCtD
Leflunomide—Headache—Sitagliptin—type 2 diabetes mellitus	8.41e-05	0.000407	CcSEcCtD
Leflunomide—Anaemia—Losartan—type 2 diabetes mellitus	8.39e-05	0.000406	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	8.35e-05	0.000404	CcSEcCtD
Leflunomide—Hypertension—Irbesartan—type 2 diabetes mellitus	8.33e-05	0.000403	CcSEcCtD
Leflunomide—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	8.31e-05	0.000402	CcSEcCtD
Leflunomide—Angioedema—Losartan—type 2 diabetes mellitus	8.3e-05	0.000401	CcSEcCtD
Leflunomide—Infection—Metformin—type 2 diabetes mellitus	8.29e-05	0.000401	CcSEcCtD
Leflunomide—Insomnia—Valsartan—type 2 diabetes mellitus	8.29e-05	0.000401	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	8.25e-05	0.000399	CcSEcCtD
Leflunomide—Paraesthesia—Valsartan—type 2 diabetes mellitus	8.23e-05	0.000398	CcSEcCtD
Leflunomide—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	8.22e-05	0.000398	CcSEcCtD
Leflunomide—Arthralgia—Irbesartan—type 2 diabetes mellitus	8.21e-05	0.000397	CcSEcCtD
Leflunomide—Myalgia—Irbesartan—type 2 diabetes mellitus	8.21e-05	0.000397	CcSEcCtD
Leflunomide—Chest pain—Irbesartan—type 2 diabetes mellitus	8.21e-05	0.000397	CcSEcCtD
Leflunomide—Insomnia—Orlistat—type 2 diabetes mellitus	8.19e-05	0.000396	CcSEcCtD
Leflunomide—Malaise—Losartan—type 2 diabetes mellitus	8.19e-05	0.000396	CcSEcCtD
Leflunomide—Anxiety—Irbesartan—type 2 diabetes mellitus	8.19e-05	0.000396	CcSEcCtD
Leflunomide—Hypersensitivity—Glyburide—type 2 diabetes mellitus	8.18e-05	0.000396	CcSEcCtD
Leflunomide—Nervous system disorder—Metformin—type 2 diabetes mellitus	8.18e-05	0.000396	CcSEcCtD
Leflunomide—Thrombocytopenia—Metformin—type 2 diabetes mellitus	8.17e-05	0.000395	CcSEcCtD
Leflunomide—Dyspnoea—Valsartan—type 2 diabetes mellitus	8.17e-05	0.000395	CcSEcCtD
Leflunomide—Vertigo—Losartan—type 2 diabetes mellitus	8.16e-05	0.000395	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	8.16e-05	0.000395	CcSEcCtD
Leflunomide—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	8.15e-05	0.000395	CcSEcCtD
Leflunomide—Paraesthesia—Orlistat—type 2 diabetes mellitus	8.13e-05	0.000393	CcSEcCtD
Leflunomide—Leukopenia—Losartan—type 2 diabetes mellitus	8.13e-05	0.000393	CcSEcCtD
Leflunomide—Discomfort—Irbesartan—type 2 diabetes mellitus	8.12e-05	0.000393	CcSEcCtD
Leflunomide—Skin disorder—Metformin—type 2 diabetes mellitus	8.1e-05	0.000392	CcSEcCtD
Leflunomide—Immune system disorder—Ramipril—type 2 diabetes mellitus	8.08e-05	0.000391	CcSEcCtD
Leflunomide—Hyperhidrosis—Metformin—type 2 diabetes mellitus	8.07e-05	0.00039	CcSEcCtD
Leflunomide—Dyspepsia—Valsartan—type 2 diabetes mellitus	8.07e-05	0.00039	CcSEcCtD
Leflunomide—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	8.06e-05	0.00039	CcSEcCtD
Leflunomide—Dizziness—Bromocriptine—type 2 diabetes mellitus	8.03e-05	0.000389	CcSEcCtD
Leflunomide—Dry mouth—Irbesartan—type 2 diabetes mellitus	8.03e-05	0.000389	CcSEcCtD
Leflunomide—Palpitations—Losartan—type 2 diabetes mellitus	8.02e-05	0.000388	CcSEcCtD
Leflunomide—Nausea—Glimepiride—type 2 diabetes mellitus	8e-05	0.000387	CcSEcCtD
Leflunomide—Arrhythmia—Ramipril—type 2 diabetes mellitus	7.99e-05	0.000387	CcSEcCtD
Leflunomide—Nausea—Sitagliptin—type 2 diabetes mellitus	7.97e-05	0.000386	CcSEcCtD
Leflunomide—Dyspepsia—Orlistat—type 2 diabetes mellitus	7.97e-05	0.000386	CcSEcCtD
Leflunomide—Asthenia—Glyburide—type 2 diabetes mellitus	7.97e-05	0.000385	CcSEcCtD
Leflunomide—Decreased appetite—Valsartan—type 2 diabetes mellitus	7.96e-05	0.000385	CcSEcCtD
Leflunomide—Anorexia—Metformin—type 2 diabetes mellitus	7.95e-05	0.000385	CcSEcCtD
Leflunomide—Cough—Losartan—type 2 diabetes mellitus	7.92e-05	0.000383	CcSEcCtD
Leflunomide—Urticaria—Gliclazide—type 2 diabetes mellitus	7.92e-05	0.000383	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	7.91e-05	0.000383	CcSEcCtD
Leflunomide—Alopecia—Ramipril—type 2 diabetes mellitus	7.9e-05	0.000382	CcSEcCtD
Leflunomide—Fatigue—Valsartan—type 2 diabetes mellitus	7.9e-05	0.000382	CcSEcCtD
Leflunomide—Body temperature increased—Gliclazide—type 2 diabetes mellitus	7.88e-05	0.000381	CcSEcCtD
Leflunomide—Abdominal pain—Gliclazide—type 2 diabetes mellitus	7.88e-05	0.000381	CcSEcCtD
Leflunomide—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	7.87e-05	0.000381	CcSEcCtD
Leflunomide—Decreased appetite—Orlistat—type 2 diabetes mellitus	7.87e-05	0.000381	CcSEcCtD
Leflunomide—Pruritus—Glyburide—type 2 diabetes mellitus	7.86e-05	0.00038	CcSEcCtD
Leflunomide—Mental disorder—Ramipril—type 2 diabetes mellitus	7.84e-05	0.000379	CcSEcCtD
Leflunomide—Constipation—Valsartan—type 2 diabetes mellitus	7.84e-05	0.000379	CcSEcCtD
Leflunomide—Infection—Irbesartan—type 2 diabetes mellitus	7.82e-05	0.000378	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	7.82e-05	0.000378	CcSEcCtD
Leflunomide—Fatigue—Orlistat—type 2 diabetes mellitus	7.81e-05	0.000378	CcSEcCtD
Leflunomide—Hypotension—Metformin—type 2 diabetes mellitus	7.8e-05	0.000377	CcSEcCtD
Leflunomide—Malnutrition—Ramipril—type 2 diabetes mellitus	7.79e-05	0.000377	CcSEcCtD
Leflunomide—Pain—Orlistat—type 2 diabetes mellitus	7.74e-05	0.000375	CcSEcCtD
Leflunomide—Arthralgia—Losartan—type 2 diabetes mellitus	7.73e-05	0.000374	CcSEcCtD
Leflunomide—Chest pain—Losartan—type 2 diabetes mellitus	7.73e-05	0.000374	CcSEcCtD
Leflunomide—Myalgia—Losartan—type 2 diabetes mellitus	7.73e-05	0.000374	CcSEcCtD
Leflunomide—Vomiting—Bromocriptine—type 2 diabetes mellitus	7.72e-05	0.000374	CcSEcCtD
Leflunomide—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	7.72e-05	0.000374	CcSEcCtD
Leflunomide—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	7.71e-05	0.000373	CcSEcCtD
Leflunomide—Anxiety—Losartan—type 2 diabetes mellitus	7.7e-05	0.000373	CcSEcCtD
Leflunomide—Tachycardia—Irbesartan—type 2 diabetes mellitus	7.68e-05	0.000372	CcSEcCtD
Leflunomide—Rash—Bromocriptine—type 2 diabetes mellitus	7.66e-05	0.000371	CcSEcCtD
Leflunomide—Dermatitis—Bromocriptine—type 2 diabetes mellitus	7.65e-05	0.00037	CcSEcCtD
Leflunomide—Skin disorder—Irbesartan—type 2 diabetes mellitus	7.65e-05	0.00037	CcSEcCtD
Leflunomide—Discomfort—Losartan—type 2 diabetes mellitus	7.64e-05	0.000369	CcSEcCtD
Leflunomide—Dysgeusia—Ramipril—type 2 diabetes mellitus	7.62e-05	0.000369	CcSEcCtD
Leflunomide—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	7.61e-05	0.000368	CcSEcCtD
Leflunomide—Headache—Bromocriptine—type 2 diabetes mellitus	7.61e-05	0.000368	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	7.6e-05	0.000368	CcSEcCtD
Leflunomide—Diarrhoea—Glyburide—type 2 diabetes mellitus	7.6e-05	0.000368	CcSEcCtD
Leflunomide—Dry mouth—Losartan—type 2 diabetes mellitus	7.56e-05	0.000366	CcSEcCtD
Leflunomide—Anorexia—Irbesartan—type 2 diabetes mellitus	7.51e-05	0.000363	CcSEcCtD
Leflunomide—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	7.49e-05	0.000362	CcSEcCtD
Leflunomide—Paraesthesia—Metformin—type 2 diabetes mellitus	7.49e-05	0.000362	CcSEcCtD
Leflunomide—Muscle spasms—Ramipril—type 2 diabetes mellitus	7.48e-05	0.000362	CcSEcCtD
Leflunomide—Feeling abnormal—Orlistat—type 2 diabetes mellitus	7.46e-05	0.000361	CcSEcCtD
Leflunomide—Dyspnoea—Metformin—type 2 diabetes mellitus	7.44e-05	0.00036	CcSEcCtD
Leflunomide—Anaphylactic shock—Losartan—type 2 diabetes mellitus	7.41e-05	0.000358	CcSEcCtD
Leflunomide—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	7.4e-05	0.000358	CcSEcCtD
Leflunomide—Infection—Losartan—type 2 diabetes mellitus	7.36e-05	0.000356	CcSEcCtD
Leflunomide—Hypotension—Irbesartan—type 2 diabetes mellitus	7.36e-05	0.000356	CcSEcCtD
Leflunomide—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	7.35e-05	0.000355	CcSEcCtD
Leflunomide—Dyspepsia—Metformin—type 2 diabetes mellitus	7.34e-05	0.000355	CcSEcCtD
Leflunomide—Urticaria—Valsartan—type 2 diabetes mellitus	7.28e-05	0.000352	CcSEcCtD
Leflunomide—Nervous system disorder—Losartan—type 2 diabetes mellitus	7.27e-05	0.000352	CcSEcCtD
Leflunomide—Thrombocytopenia—Losartan—type 2 diabetes mellitus	7.26e-05	0.000351	CcSEcCtD
Leflunomide—Decreased appetite—Metformin—type 2 diabetes mellitus	7.25e-05	0.000351	CcSEcCtD
Leflunomide—Abdominal pain—Valsartan—type 2 diabetes mellitus	7.24e-05	0.00035	CcSEcCtD
Leflunomide—Tachycardia—Losartan—type 2 diabetes mellitus	7.23e-05	0.00035	CcSEcCtD
Leflunomide—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	7.22e-05	0.000349	CcSEcCtD
Leflunomide—Nausea—Bromocriptine—type 2 diabetes mellitus	7.22e-05	0.000349	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	7.2e-05	0.000348	CcSEcCtD
Leflunomide—Fatigue—Metformin—type 2 diabetes mellitus	7.19e-05	0.000348	CcSEcCtD
Leflunomide—Urticaria—Orlistat—type 2 diabetes mellitus	7.19e-05	0.000348	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	7.17e-05	0.000347	CcSEcCtD
Leflunomide—Hyperhidrosis—Losartan—type 2 diabetes mellitus	7.16e-05	0.000347	CcSEcCtD
Leflunomide—Abdominal pain—Orlistat—type 2 diabetes mellitus	7.16e-05	0.000346	CcSEcCtD
Leflunomide—Body temperature increased—Orlistat—type 2 diabetes mellitus	7.16e-05	0.000346	CcSEcCtD
Leflunomide—Asthenia—Gliclazide—type 2 diabetes mellitus	7.15e-05	0.000346	CcSEcCtD
Leflunomide—Constipation—Metformin—type 2 diabetes mellitus	7.13e-05	0.000345	CcSEcCtD
Leflunomide—Angioedema—Ramipril—type 2 diabetes mellitus	7.11e-05	0.000344	CcSEcCtD
Leflunomide—Paraesthesia—Irbesartan—type 2 diabetes mellitus	7.07e-05	0.000342	CcSEcCtD
Leflunomide—Anorexia—Losartan—type 2 diabetes mellitus	7.06e-05	0.000342	CcSEcCtD
Leflunomide—Vomiting—Glyburide—type 2 diabetes mellitus	7.06e-05	0.000342	CcSEcCtD
Leflunomide—Pruritus—Gliclazide—type 2 diabetes mellitus	7.06e-05	0.000341	CcSEcCtD
Leflunomide—Malaise—Ramipril—type 2 diabetes mellitus	7.02e-05	0.00034	CcSEcCtD
Leflunomide—Dyspnoea—Irbesartan—type 2 diabetes mellitus	7.02e-05	0.00034	CcSEcCtD
Leflunomide—Rash—Glyburide—type 2 diabetes mellitus	7e-05	0.000339	CcSEcCtD
Leflunomide—Dermatitis—Glyburide—type 2 diabetes mellitus	7e-05	0.000338	CcSEcCtD
Leflunomide—Vertigo—Ramipril—type 2 diabetes mellitus	6.99e-05	0.000338	CcSEcCtD
Leflunomide—Leukopenia—Ramipril—type 2 diabetes mellitus	6.97e-05	0.000337	CcSEcCtD
Leflunomide—Headache—Glyburide—type 2 diabetes mellitus	6.96e-05	0.000337	CcSEcCtD
Leflunomide—Dyspepsia—Irbesartan—type 2 diabetes mellitus	6.93e-05	0.000335	CcSEcCtD
Leflunomide—Hypotension—Losartan—type 2 diabetes mellitus	6.92e-05	0.000335	CcSEcCtD
Leflunomide—Palpitations—Ramipril—type 2 diabetes mellitus	6.88e-05	0.000333	CcSEcCtD
Leflunomide—Feeling abnormal—Metformin—type 2 diabetes mellitus	6.88e-05	0.000333	CcSEcCtD
Leflunomide—Decreased appetite—Irbesartan—type 2 diabetes mellitus	6.84e-05	0.000331	CcSEcCtD
Leflunomide—Diarrhoea—Gliclazide—type 2 diabetes mellitus	6.82e-05	0.00033	CcSEcCtD
Leflunomide—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	6.82e-05	0.00033	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	6.8e-05	0.000329	CcSEcCtD
Leflunomide—Cough—Ramipril—type 2 diabetes mellitus	6.79e-05	0.000329	CcSEcCtD
Leflunomide—Fatigue—Irbesartan—type 2 diabetes mellitus	6.79e-05	0.000328	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	6.75e-05	0.000327	CcSEcCtD
Leflunomide—Hypersensitivity—Valsartan—type 2 diabetes mellitus	6.75e-05	0.000327	CcSEcCtD
Leflunomide—Pain—Irbesartan—type 2 diabetes mellitus	6.73e-05	0.000326	CcSEcCtD
Leflunomide—Constipation—Irbesartan—type 2 diabetes mellitus	6.73e-05	0.000326	CcSEcCtD
Leflunomide—Insomnia—Losartan—type 2 diabetes mellitus	6.7e-05	0.000324	CcSEcCtD
Leflunomide—Hypersensitivity—Orlistat—type 2 diabetes mellitus	6.67e-05	0.000323	CcSEcCtD
Leflunomide—Paraesthesia—Losartan—type 2 diabetes mellitus	6.65e-05	0.000322	CcSEcCtD
Leflunomide—Urticaria—Metformin—type 2 diabetes mellitus	6.63e-05	0.000321	CcSEcCtD
Leflunomide—Arthralgia—Ramipril—type 2 diabetes mellitus	6.63e-05	0.000321	CcSEcCtD
Leflunomide—Myalgia—Ramipril—type 2 diabetes mellitus	6.63e-05	0.000321	CcSEcCtD
Leflunomide—Chest pain—Ramipril—type 2 diabetes mellitus	6.63e-05	0.000321	CcSEcCtD
Leflunomide—Dyspnoea—Losartan—type 2 diabetes mellitus	6.61e-05	0.00032	CcSEcCtD
Leflunomide—Anxiety—Ramipril—type 2 diabetes mellitus	6.61e-05	0.00032	CcSEcCtD
Leflunomide—Nausea—Glyburide—type 2 diabetes mellitus	6.6e-05	0.000319	CcSEcCtD
Leflunomide—Abdominal pain—Metformin—type 2 diabetes mellitus	6.6e-05	0.000319	CcSEcCtD
Leflunomide—Dizziness—Gliclazide—type 2 diabetes mellitus	6.59e-05	0.000319	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	6.58e-05	0.000318	CcSEcCtD
Leflunomide—Asthenia—Valsartan—type 2 diabetes mellitus	6.57e-05	0.000318	CcSEcCtD
Leflunomide—Discomfort—Ramipril—type 2 diabetes mellitus	6.55e-05	0.000317	CcSEcCtD
Leflunomide—Dyspepsia—Losartan—type 2 diabetes mellitus	6.52e-05	0.000316	CcSEcCtD
Leflunomide—Asthenia—Orlistat—type 2 diabetes mellitus	6.5e-05	0.000314	CcSEcCtD
Leflunomide—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	6.49e-05	0.000314	CcSEcCtD
Leflunomide—Pruritus—Valsartan—type 2 diabetes mellitus	6.48e-05	0.000314	CcSEcCtD
Leflunomide—Dry mouth—Ramipril—type 2 diabetes mellitus	6.48e-05	0.000314	CcSEcCtD
Leflunomide—Decreased appetite—Losartan—type 2 diabetes mellitus	6.44e-05	0.000312	CcSEcCtD
Leflunomide—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	6.44e-05	0.000311	CcSEcCtD
Leflunomide—Pruritus—Orlistat—type 2 diabetes mellitus	6.41e-05	0.00031	CcSEcCtD
Leflunomide—Fatigue—Losartan—type 2 diabetes mellitus	6.39e-05	0.000309	CcSEcCtD
Leflunomide—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	6.35e-05	0.000307	CcSEcCtD
Leflunomide—Vomiting—Gliclazide—type 2 diabetes mellitus	6.34e-05	0.000307	CcSEcCtD
Leflunomide—Pain—Losartan—type 2 diabetes mellitus	6.34e-05	0.000307	CcSEcCtD
Leflunomide—Constipation—Losartan—type 2 diabetes mellitus	6.34e-05	0.000307	CcSEcCtD
Leflunomide—Rash—Gliclazide—type 2 diabetes mellitus	6.29e-05	0.000304	CcSEcCtD
Leflunomide—Dermatitis—Gliclazide—type 2 diabetes mellitus	6.28e-05	0.000304	CcSEcCtD
Leflunomide—Diarrhoea—Valsartan—type 2 diabetes mellitus	6.27e-05	0.000303	CcSEcCtD
Leflunomide—Urticaria—Irbesartan—type 2 diabetes mellitus	6.26e-05	0.000303	CcSEcCtD
Leflunomide—Headache—Gliclazide—type 2 diabetes mellitus	6.25e-05	0.000302	CcSEcCtD
Leflunomide—Nervous system disorder—Ramipril—type 2 diabetes mellitus	6.23e-05	0.000301	CcSEcCtD
Leflunomide—Body temperature increased—Irbesartan—type 2 diabetes mellitus	6.22e-05	0.000301	CcSEcCtD
Leflunomide—Abdominal pain—Irbesartan—type 2 diabetes mellitus	6.22e-05	0.000301	CcSEcCtD
Leflunomide—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	6.22e-05	0.000301	CcSEcCtD
Leflunomide—Tachycardia—Ramipril—type 2 diabetes mellitus	6.2e-05	0.0003	CcSEcCtD
Leflunomide—Diarrhoea—Orlistat—type 2 diabetes mellitus	6.19e-05	0.0003	CcSEcCtD
Leflunomide—Skin disorder—Ramipril—type 2 diabetes mellitus	6.17e-05	0.000299	CcSEcCtD
Leflunomide—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	6.14e-05	0.000297	CcSEcCtD
Leflunomide—Feeling abnormal—Losartan—type 2 diabetes mellitus	6.11e-05	0.000295	CcSEcCtD
Leflunomide—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	6.06e-05	0.000293	CcSEcCtD
Leflunomide—Dizziness—Valsartan—type 2 diabetes mellitus	6.06e-05	0.000293	CcSEcCtD
Leflunomide—Anorexia—Ramipril—type 2 diabetes mellitus	6.06e-05	0.000293	CcSEcCtD
Leflunomide—Dizziness—Orlistat—type 2 diabetes mellitus	5.99e-05	0.00029	CcSEcCtD
Leflunomide—Asthenia—Metformin—type 2 diabetes mellitus	5.99e-05	0.00029	CcSEcCtD
Leflunomide—Hypotension—Ramipril—type 2 diabetes mellitus	5.94e-05	0.000287	CcSEcCtD
Leflunomide—Nausea—Gliclazide—type 2 diabetes mellitus	5.92e-05	0.000287	CcSEcCtD
Leflunomide—Pruritus—Metformin—type 2 diabetes mellitus	5.9e-05	0.000286	CcSEcCtD
Leflunomide—Urticaria—Losartan—type 2 diabetes mellitus	5.89e-05	0.000285	CcSEcCtD
Leflunomide—Abdominal pain—Losartan—type 2 diabetes mellitus	5.86e-05	0.000283	CcSEcCtD
Leflunomide—Body temperature increased—Losartan—type 2 diabetes mellitus	5.86e-05	0.000283	CcSEcCtD
Leflunomide—Vomiting—Valsartan—type 2 diabetes mellitus	5.83e-05	0.000282	CcSEcCtD
Leflunomide—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	5.8e-05	0.000281	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	5.79e-05	0.00028	CcSEcCtD
Leflunomide—Rash—Valsartan—type 2 diabetes mellitus	5.78e-05	0.000279	CcSEcCtD
Leflunomide—Dermatitis—Valsartan—type 2 diabetes mellitus	5.77e-05	0.000279	CcSEcCtD
Leflunomide—Vomiting—Orlistat—type 2 diabetes mellitus	5.76e-05	0.000278	CcSEcCtD
Leflunomide—Insomnia—Ramipril—type 2 diabetes mellitus	5.75e-05	0.000278	CcSEcCtD
Leflunomide—Headache—Valsartan—type 2 diabetes mellitus	5.74e-05	0.000278	CcSEcCtD
Leflunomide—Diarrhoea—Metformin—type 2 diabetes mellitus	5.71e-05	0.000276	CcSEcCtD
Leflunomide—Rash—Orlistat—type 2 diabetes mellitus	5.71e-05	0.000276	CcSEcCtD
Leflunomide—Paraesthesia—Ramipril—type 2 diabetes mellitus	5.71e-05	0.000276	CcSEcCtD
Leflunomide—Dermatitis—Orlistat—type 2 diabetes mellitus	5.7e-05	0.000276	CcSEcCtD
Leflunomide—Headache—Orlistat—type 2 diabetes mellitus	5.67e-05	0.000274	CcSEcCtD
Leflunomide—Dyspnoea—Ramipril—type 2 diabetes mellitus	5.66e-05	0.000274	CcSEcCtD
Leflunomide—Asthenia—Irbesartan—type 2 diabetes mellitus	5.65e-05	0.000273	CcSEcCtD
Leflunomide—Dyspepsia—Ramipril—type 2 diabetes mellitus	5.59e-05	0.000271	CcSEcCtD
Leflunomide—Pruritus—Irbesartan—type 2 diabetes mellitus	5.57e-05	0.00027	CcSEcCtD
Leflunomide—Decreased appetite—Ramipril—type 2 diabetes mellitus	5.52e-05	0.000267	CcSEcCtD
Leflunomide—Dizziness—Metformin—type 2 diabetes mellitus	5.52e-05	0.000267	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	5.49e-05	0.000265	CcSEcCtD
Leflunomide—Fatigue—Ramipril—type 2 diabetes mellitus	5.48e-05	0.000265	CcSEcCtD
Leflunomide—Hypersensitivity—Losartan—type 2 diabetes mellitus	5.46e-05	0.000264	CcSEcCtD
Leflunomide—Nausea—Valsartan—type 2 diabetes mellitus	5.44e-05	0.000263	CcSEcCtD
Leflunomide—Constipation—Ramipril—type 2 diabetes mellitus	5.43e-05	0.000263	CcSEcCtD
Leflunomide—Diarrhoea—Irbesartan—type 2 diabetes mellitus	5.39e-05	0.000261	CcSEcCtD
Leflunomide—Nausea—Orlistat—type 2 diabetes mellitus	5.38e-05	0.00026	CcSEcCtD
Leflunomide—Asthenia—Losartan—type 2 diabetes mellitus	5.32e-05	0.000257	CcSEcCtD
Leflunomide—Vomiting—Metformin—type 2 diabetes mellitus	5.3e-05	0.000257	CcSEcCtD
Leflunomide—Rash—Metformin—type 2 diabetes mellitus	5.26e-05	0.000255	CcSEcCtD
Leflunomide—Dermatitis—Metformin—type 2 diabetes mellitus	5.26e-05	0.000254	CcSEcCtD
Leflunomide—Pruritus—Losartan—type 2 diabetes mellitus	5.24e-05	0.000254	CcSEcCtD
Leflunomide—Feeling abnormal—Ramipril—type 2 diabetes mellitus	5.24e-05	0.000253	CcSEcCtD
Leflunomide—Headache—Metformin—type 2 diabetes mellitus	5.23e-05	0.000253	CcSEcCtD
Leflunomide—Dizziness—Irbesartan—type 2 diabetes mellitus	5.21e-05	0.000252	CcSEcCtD
Leflunomide—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	5.2e-05	0.000251	CcSEcCtD
Leflunomide—Diarrhoea—Losartan—type 2 diabetes mellitus	5.07e-05	0.000245	CcSEcCtD
Leflunomide—Urticaria—Ramipril—type 2 diabetes mellitus	5.05e-05	0.000244	CcSEcCtD
Leflunomide—Body temperature increased—Ramipril—type 2 diabetes mellitus	5.02e-05	0.000243	CcSEcCtD
Leflunomide—Abdominal pain—Ramipril—type 2 diabetes mellitus	5.02e-05	0.000243	CcSEcCtD
Leflunomide—Vomiting—Irbesartan—type 2 diabetes mellitus	5.01e-05	0.000242	CcSEcCtD
Leflunomide—Rash—Irbesartan—type 2 diabetes mellitus	4.96e-05	0.00024	CcSEcCtD
Leflunomide—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.96e-05	0.00024	CcSEcCtD
Leflunomide—Nausea—Metformin—type 2 diabetes mellitus	4.96e-05	0.00024	CcSEcCtD
Leflunomide—Headache—Irbesartan—type 2 diabetes mellitus	4.93e-05	0.000239	CcSEcCtD
Leflunomide—Dizziness—Losartan—type 2 diabetes mellitus	4.9e-05	0.000237	CcSEcCtD
Leflunomide—Vomiting—Losartan—type 2 diabetes mellitus	4.71e-05	0.000228	CcSEcCtD
Leflunomide—Hypersensitivity—Ramipril—type 2 diabetes mellitus	4.68e-05	0.000226	CcSEcCtD
Leflunomide—Nausea—Irbesartan—type 2 diabetes mellitus	4.68e-05	0.000226	CcSEcCtD
Leflunomide—Rash—Losartan—type 2 diabetes mellitus	4.67e-05	0.000226	CcSEcCtD
Leflunomide—Dermatitis—Losartan—type 2 diabetes mellitus	4.67e-05	0.000226	CcSEcCtD
Leflunomide—Headache—Losartan—type 2 diabetes mellitus	4.64e-05	0.000225	CcSEcCtD
Leflunomide—Asthenia—Ramipril—type 2 diabetes mellitus	4.56e-05	0.000221	CcSEcCtD
Leflunomide—Pruritus—Ramipril—type 2 diabetes mellitus	4.5e-05	0.000217	CcSEcCtD
Leflunomide—Nausea—Losartan—type 2 diabetes mellitus	4.4e-05	0.000213	CcSEcCtD
Leflunomide—Diarrhoea—Ramipril—type 2 diabetes mellitus	4.35e-05	0.00021	CcSEcCtD
Leflunomide—Dizziness—Ramipril—type 2 diabetes mellitus	4.2e-05	0.000203	CcSEcCtD
Leflunomide—Vomiting—Ramipril—type 2 diabetes mellitus	4.04e-05	0.000195	CcSEcCtD
Leflunomide—Rash—Ramipril—type 2 diabetes mellitus	4.01e-05	0.000194	CcSEcCtD
Leflunomide—Dermatitis—Ramipril—type 2 diabetes mellitus	4e-05	0.000194	CcSEcCtD
Leflunomide—Headache—Ramipril—type 2 diabetes mellitus	3.98e-05	0.000193	CcSEcCtD
Leflunomide—Nausea—Ramipril—type 2 diabetes mellitus	3.77e-05	0.000183	CcSEcCtD
Leflunomide—CYP2C9—Metabolism—G6PC—type 2 diabetes mellitus	1.47e-05	0.000158	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HBA2—type 2 diabetes mellitus	1.47e-05	0.000158	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC9A1—type 2 diabetes mellitus	1.45e-05	0.000156	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—type 2 diabetes mellitus	1.44e-05	0.000155	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CETP—type 2 diabetes mellitus	1.43e-05	0.000154	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—type 2 diabetes mellitus	1.43e-05	0.000154	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GCGR—type 2 diabetes mellitus	1.42e-05	0.000153	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AK1—type 2 diabetes mellitus	1.41e-05	0.000151	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.4e-05	0.000151	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.4e-05	0.00015	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AGT—type 2 diabetes mellitus	1.4e-05	0.00015	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CETP—type 2 diabetes mellitus	1.39e-05	0.00015	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.37e-05	0.000148	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APOE—type 2 diabetes mellitus	1.37e-05	0.000147	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—LEP—type 2 diabetes mellitus	1.37e-05	0.000147	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—type 2 diabetes mellitus	1.37e-05	0.000147	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.35e-05	0.000145	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYTB—type 2 diabetes mellitus	1.34e-05	0.000144	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—OXCT1—type 2 diabetes mellitus	1.34e-05	0.000144	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SREBF1—type 2 diabetes mellitus	1.33e-05	0.000143	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SNAP25—type 2 diabetes mellitus	1.33e-05	0.000143	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PSMD6—type 2 diabetes mellitus	1.33e-05	0.000143	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CTGF—type 2 diabetes mellitus	1.31e-05	0.000141	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SRD5A1—type 2 diabetes mellitus	1.31e-05	0.000141	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC5A4—type 2 diabetes mellitus	1.3e-05	0.00014	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MAT1A—type 2 diabetes mellitus	1.3e-05	0.00014	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HMGCR—type 2 diabetes mellitus	1.3e-05	0.00014	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—SREBF1—type 2 diabetes mellitus	1.29e-05	0.000139	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.29e-05	0.000139	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	1.27e-05	0.000137	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ADRA2A—type 2 diabetes mellitus	1.27e-05	0.000137	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—type 2 diabetes mellitus	1.27e-05	0.000136	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NFKB1—type 2 diabetes mellitus	1.26e-05	0.000135	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—type 2 diabetes mellitus	1.26e-05	0.000135	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HBA2—type 2 diabetes mellitus	1.25e-05	0.000135	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—G6PC—type 2 diabetes mellitus	1.25e-05	0.000135	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.25e-05	0.000135	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ENPP1—type 2 diabetes mellitus	1.25e-05	0.000135	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ND1—type 2 diabetes mellitus	1.25e-05	0.000135	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—STAR—type 2 diabetes mellitus	1.25e-05	0.000134	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ACACA—type 2 diabetes mellitus	1.25e-05	0.000134	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HSD17B3—type 2 diabetes mellitus	1.25e-05	0.000134	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.22e-05	0.000131	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP2E1—type 2 diabetes mellitus	1.22e-05	0.000131	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GCGR—type 2 diabetes mellitus	1.21e-05	0.000131	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP1A2—type 2 diabetes mellitus	1.21e-05	0.00013	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC2A1—type 2 diabetes mellitus	1.21e-05	0.00013	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CBS—type 2 diabetes mellitus	1.2e-05	0.000129	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCC8—type 2 diabetes mellitus	1.2e-05	0.000129	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP3A4—type 2 diabetes mellitus	1.18e-05	0.000127	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—SRC—type 2 diabetes mellitus	1.17e-05	0.000126	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—INS—type 2 diabetes mellitus	1.17e-05	0.000126	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GCG—type 2 diabetes mellitus	1.16e-05	0.000124	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC2A4—type 2 diabetes mellitus	1.16e-05	0.000124	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—COX2—type 2 diabetes mellitus	1.15e-05	0.000124	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC5A2—type 2 diabetes mellitus	1.15e-05	0.000124	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.15e-05	0.000124	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYTB—type 2 diabetes mellitus	1.15e-05	0.000123	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—OXCT1—type 2 diabetes mellitus	1.15e-05	0.000123	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NCOA6—type 2 diabetes mellitus	1.13e-05	0.000122	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.13e-05	0.000122	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARGC1A—type 2 diabetes mellitus	1.13e-05	0.000122	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.13e-05	0.000122	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SRD5A1—type 2 diabetes mellitus	1.12e-05	0.00012	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HSD11B1—type 2 diabetes mellitus	1.11e-05	0.00012	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—UCP2—type 2 diabetes mellitus	1.11e-05	0.00012	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—UCP3—type 2 diabetes mellitus	1.11e-05	0.00012	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOB—type 2 diabetes mellitus	1.08e-05	0.000116	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.07e-05	0.000115	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ACACA—type 2 diabetes mellitus	1.07e-05	0.000115	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HSD17B3—type 2 diabetes mellitus	1.07e-05	0.000115	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—STAR—type 2 diabetes mellitus	1.07e-05	0.000115	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PCK1—type 2 diabetes mellitus	1.05e-05	0.000112	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—LPL—type 2 diabetes mellitus	1.03e-05	0.000111	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—type 2 diabetes mellitus	1.03e-05	0.000111	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.02e-05	0.00011	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.02e-05	0.00011	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCC8—type 2 diabetes mellitus	1.02e-05	0.00011	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CBS—type 2 diabetes mellitus	1.02e-05	0.00011	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—type 2 diabetes mellitus	1e-05	0.000108	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GNB3—type 2 diabetes mellitus	9.97e-06	0.000107	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARGC1A—type 2 diabetes mellitus	9.97e-06	0.000107	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HMOX1—type 2 diabetes mellitus	9.92e-06	0.000107	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—COX2—type 2 diabetes mellitus	9.84e-06	0.000106	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC5A2—type 2 diabetes mellitus	9.84e-06	0.000106	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CAT—type 2 diabetes mellitus	9.79e-06	0.000105	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HK1—type 2 diabetes mellitus	9.79e-06	0.000105	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CD36—type 2 diabetes mellitus	9.78e-06	0.000105	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NCOA6—type 2 diabetes mellitus	9.66e-06	0.000104	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—type 2 diabetes mellitus	9.66e-06	0.000104	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RELA—type 2 diabetes mellitus	9.65e-06	0.000104	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOB—type 2 diabetes mellitus	9.5e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—UCP2—type 2 diabetes mellitus	9.5e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—UCP3—type 2 diabetes mellitus	9.5e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HSD11B1—type 2 diabetes mellitus	9.5e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LPA—type 2 diabetes mellitus	9.45e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—KCNJ11—type 2 diabetes mellitus	9.45e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HSD3B2—type 2 diabetes mellitus	9.45e-06	0.000102	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GCKR—type 2 diabetes mellitus	9.45e-06	0.000102	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTM1—type 2 diabetes mellitus	9.24e-06	9.94e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOB—type 2 diabetes mellitus	9.21e-06	9.91e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	9.09e-06	9.78e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—LPL—type 2 diabetes mellitus	9.07e-06	9.76e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALDOB—type 2 diabetes mellitus	9.06e-06	9.75e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PCK1—type 2 diabetes mellitus	8.93e-06	9.61e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ADCY5—type 2 diabetes mellitus	8.88e-06	9.56e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPX1—type 2 diabetes mellitus	8.85e-06	9.52e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	8.8e-06	9.47e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—type 2 diabetes mellitus	8.79e-06	9.46e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.7e-06	9.36e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	8.62e-06	9.28e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CD36—type 2 diabetes mellitus	8.62e-06	9.27e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—type 2 diabetes mellitus	8.58e-06	9.23e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	8.53e-06	9.17e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPP2CA—type 2 diabetes mellitus	8.51e-06	9.16e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GLP1R—type 2 diabetes mellitus	8.43e-06	9.06e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HK1—type 2 diabetes mellitus	8.36e-06	9e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—type 2 diabetes mellitus	8.35e-06	8.99e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.22e-06	8.85e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—MTHFR—type 2 diabetes mellitus	8.17e-06	8.79e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.13e-06	8.75e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GCKR—type 2 diabetes mellitus	8.08e-06	8.69e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—KCNJ11—type 2 diabetes mellitus	8.08e-06	8.69e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HSD3B2—type 2 diabetes mellitus	8.08e-06	8.69e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LPA—type 2 diabetes mellitus	8.08e-06	8.69e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARA—type 2 diabetes mellitus	8.01e-06	8.62e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL6—type 2 diabetes mellitus	7.9e-06	8.5e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC2A2—type 2 diabetes mellitus	7.87e-06	8.46e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	7.77e-06	8.36e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AGT—type 2 diabetes mellitus	7.76e-06	8.35e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALDOB—type 2 diabetes mellitus	7.74e-06	8.33e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CPT1A—type 2 diabetes mellitus	7.71e-06	8.29e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTR—type 2 diabetes mellitus	7.71e-06	8.29e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CALM1—type 2 diabetes mellitus	7.63e-06	8.21e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOE—type 2 diabetes mellitus	7.61e-06	8.18e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SRC—type 2 diabetes mellitus	7.58e-06	8.16e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NAMPT—type 2 diabetes mellitus	7.56e-06	8.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	7.52e-06	8.09e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—APOA1—type 2 diabetes mellitus	7.52e-06	8.09e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	7.51e-06	8.08e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LIPC—type 2 diabetes mellitus	7.51e-06	8.08e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HBA1—type 2 diabetes mellitus	7.51e-06	8.08e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GCK—type 2 diabetes mellitus	7.51e-06	8.08e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP11A1—type 2 diabetes mellitus	7.46e-06	8.03e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.38e-06	7.94e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	7.37e-06	7.93e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC9A1—type 2 diabetes mellitus	7.33e-06	7.89e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	7.29e-06	7.84e-05	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—type 2 diabetes mellitus	7.29e-06	7.84e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CETP—type 2 diabetes mellitus	7.24e-06	7.79e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GLP1R—type 2 diabetes mellitus	7.2e-06	7.75e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.78e-06	7.29e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	6.76e-06	7.27e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SNAP25—type 2 diabetes mellitus	6.74e-06	7.25e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SREBF1—type 2 diabetes mellitus	6.74e-06	7.25e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PSMD6—type 2 diabetes mellitus	6.74e-06	7.25e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC2A2—type 2 diabetes mellitus	6.72e-06	7.23e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.64e-06	7.15e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARG—type 2 diabetes mellitus	6.62e-06	7.13e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CTGF—type 2 diabetes mellitus	6.61e-06	7.11e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTR—type 2 diabetes mellitus	6.58e-06	7.08e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CPT1A—type 2 diabetes mellitus	6.58e-06	7.08e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HMGCR—type 2 diabetes mellitus	6.55e-06	7.05e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—INS—type 2 diabetes mellitus	6.5e-06	6.99e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	6.46e-06	6.95e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NAMPT—type 2 diabetes mellitus	6.46e-06	6.95e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	6.42e-06	6.91e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LIPC—type 2 diabetes mellitus	6.42e-06	6.9e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HBA1—type 2 diabetes mellitus	6.42e-06	6.9e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GCK—type 2 diabetes mellitus	6.42e-06	6.9e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ADRA2A—type 2 diabetes mellitus	6.41e-06	6.9e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP11A1—type 2 diabetes mellitus	6.38e-06	6.86e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	6.26e-06	6.74e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	6.19e-06	6.66e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP2E1—type 2 diabetes mellitus	6.16e-06	6.63e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC2A1—type 2 diabetes mellitus	6.09e-06	6.55e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP1A2—type 2 diabetes mellitus	6.09e-06	6.55e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ALB—type 2 diabetes mellitus	5.96e-06	6.41e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	5.94e-06	6.39e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	5.91e-06	6.36e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	5.84e-06	6.28e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	5.84e-06	6.28e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	5.77e-06	6.21e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	5.76e-06	6.19e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	5.76e-06	6.19e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	5.76e-06	6.19e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3R1—type 2 diabetes mellitus	5.7e-06	6.13e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NOS3—type 2 diabetes mellitus	5.7e-06	6.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	5.65e-06	6.08e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	5.6e-06	6.02e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	5.52e-06	5.94e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	5.48e-06	5.89e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	5.26e-06	5.66e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	5.21e-06	5.61e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	5.21e-06	5.6e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL6—type 2 diabetes mellitus	5.11e-06	5.49e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	5.08e-06	5.46e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	5.05e-06	5.43e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	5.03e-06	5.42e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.03e-06	5.42e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	5.01e-06	5.39e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	4.99e-06	5.37e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	4.99e-06	5.37e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	4.94e-06	5.32e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	4.8e-06	5.16e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.71e-06	5.07e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	4.67e-06	5.02e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	4.58e-06	4.93e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	4.49e-06	4.83e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	4.47e-06	4.81e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	4.35e-06	4.68e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.3e-06	4.63e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	4.3e-06	4.63e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	4.3e-06	4.63e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	4.28e-06	4.61e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	4.22e-06	4.54e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	4.13e-06	4.44e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	4.1e-06	4.41e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	4.05e-06	4.35e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	3.99e-06	4.29e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	3.92e-06	4.22e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	3.92e-06	4.21e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	3.85e-06	4.15e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	3.84e-06	4.13e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	3.83e-06	4.12e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	3.82e-06	4.11e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	3.8e-06	4.09e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	3.72e-06	4e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	3.67e-06	3.95e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	3.53e-06	3.79e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	3.46e-06	3.72e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	3.35e-06	3.6e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	3.35e-06	3.6e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	3.29e-06	3.54e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	3.28e-06	3.53e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	3.28e-06	3.53e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	3.24e-06	3.49e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	3.01e-06	3.24e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	2.88e-06	3.1e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	2.88e-06	3.1e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	2.86e-06	3.08e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	2.8e-06	3.02e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	2.63e-06	2.83e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	2.62e-06	2.82e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	2.57e-06	2.77e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	2.46e-06	2.65e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	2.46e-06	2.65e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	2.25e-06	2.42e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	1.32e-06	1.42e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	1.13e-06	1.22e-05	CbGpPWpGaD
